Search results for "respiratory tract diseases"

showing 10 items of 1015 documents

Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease

2005

Current therapy for chronic obstructive pulmonary disease (COPD) fails to alter its relentless progression. This remains a significant challenge and unmet need. A recent advance is the demonstration that treatment with a fixed dose of an inhaled corticosteroid and a long-acting beta2-agonist in COPD improves lung function and quality of life, and reduces exacerbation more effectively than either drug alone. Other improvements include the introduction of tiotropium, a once-daily anticholinergic. In advanced clinical development are other once-daily bronchodilators and combinations of anticholinergic drugs and beta2-agonists. Increased understanding of the pathogenesis of COPD has led to nove…

Pulmonary and Respiratory MedicineDrugmedicine.medical_specialtyExacerbationPhosphodiesterase Inhibitorsmedicine.drug_classmedia_common.quotation_subjectAnti-Inflammatory AgentsPharmacologySystemic inflammationAntioxidantsPathogenesisPulmonary Disease Chronic ObstructiveAdministration InhalationAnticholinergicmedicineHumansProtease InhibitorsIntensive care medicineGlucocorticoidsmedia_commonCOPDInhalationbusiness.industryAntibodies MonoclonalAdrenergic beta-Agonistsmedicine.diseaseBronchodilator Agentsrespiratory tract diseasesDrug developmentQuality of LifeSmoking Cessationmedicine.symptombusinessProceedings of the American Thoracic Society
researchProduct

Lung penetration and patient adherence considerations in the management of asthma: role of extra fine formulations

2013

The mainstay of management in asthma is inhalation therapy at the target site, with direct delivery of the aerosolized drug into the airways to treat inflammation and relieve obstruction. Abundant evidence is available to support the concept that inflammatory and functional changes at the level of the most peripheral airways strongly contribute to the complexity and heterogeneous manifestations of asthma. It is now largely accepted that there is a wide range of clinical phenotypes of the disease, characterized primarily by small airways involvement. Thus, an appropriate diagnostic algorithm cannot exclude biological and functional assessment of the peripheral airways. Similarly, achievement…

Pulmonary and Respiratory MedicineDrugmedicine.medical_specialtyPathologymedia_common.quotation_subjectDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioQuality of life (healthcare)Asthma controlJournal of Asthma and AllergymedicineImmunology and AllergyIntensive care medicinedeviceOriginal Researchmedia_commonAsthmasmall airwaysLungInhalationbusiness.industrySmall airwaysasthmarespiratory systemmedicine.diseaserespiratory tract diseasesmedicine.anatomical_structurequality of lifeinflammationCorrigendumbusinessJournal of Asthma and Allergy
researchProduct

Interstitial lung disease induced by drugs and radiation.

2004

An ever-increasing number of drugs can reproduce variegated patterns of naturally occurring interstitial lung disease (ILD), including most forms of interstitial pneumonias, alveolar involvement and, rarely, vasculitis. Drugs in one therapeutic class may collectively produce the same pattern of involvement. A few drugs can produce more than one pattern of ILD. The diagnosis of drug-induced ILD (DI-ILD) essentially rests on the temporal association between exposure to the drug and the development of pulmonary infiltrates. The histopathological features of DI-ILD are generally consistent, rather than suggestive or specific to the drug etiology. Thus, the diagnosis of DI-ILD is mainly made by …

Pulmonary and Respiratory MedicineDrugmedicine.medical_specialtyPathologymedia_common.quotation_subjectPulmonary FibrosisAmiodaronePulmonary EdemaMedicineHumansInterstitial pneumoniaPulmonary EosinophiliaDechallengeBronchiolitis ObliteransLungmedia_commonRadiotherapybusiness.industryRespiratory diseaseInterstitial lung diseasePneumoniarespiratory systemmedicine.diseaseDermatologyrespiratory tract diseasesPulmonary AlveoliRadiographyMethotrexateCorticosteroid therapyChronic DiseaseEtiologybusinessVasculitisLung Diseases InterstitialRespiration; international review of thoracic diseases
researchProduct

Cigarette smoke exposure inhibits extracellular MMP-2 (gelatinase A) activity in human lung fibroblasts

2007

Abstract Background Exposure to cigarette smoke is considered a major risk factor for the development of lung diseases, since its causative role has been assessed in the induction and maintenance of an inflamed state in the airways. Lung fibroblasts can contribute to these processes, due to their ability to produce proinflammatory chemotactic molecules and extracellular matrix remodelling proteinases. Among proteolytic enzymes, gelatinases A and B have been studied for their role in tissue breakdown and mobilisation of matrix-derived signalling molecules. Multiple reports linked gelatinase deregulation and overexpression to the development of inflammatory chronic lung diseases such as COPD.…

Pulmonary and Respiratory MedicineGelatinase ABiologyMatrix metalloproteinaseProinflammatory cytokineExtracellular matrixExtracellularHumansGelatinaseRNA MessengerLungCells Culturedlcsh:RC705-779Cell DeathPlant ExtractsResearchProteolytic enzymessmoke MMP-2Tissue Inhibitor of MetalloproteinasesEnvironmental Exposurelcsh:Diseases of the respiratory systemEnvironmental exposureFibroblastsrespiratory systemrespiratory tract diseasesCulture Media ConditionedImmunologyMatrix Metalloproteinase 2Tobacco Smoke PollutionEnvironmental MonitoringRespiratory Research
researchProduct

Mucus and MUC in asthma.

2005

Asthma is characterized by chronic airway inflammation and a mucus hypersecretory phenotype comprising excess mucus secretion, goblet cell hyperplasia and submucosal gland hypertrophy. This augmented mucus secretion has been relatively undervalued in asthma compared with airway inflammation. However, mucus plugging contributes to airflow limitation and airway hyperresponsiveness, and to morbidity and mortality in asthma. We review recent contributions to this field and therapeutic avenues to control mucus hypersecretion.A distinct mucus hypersecretory phenotype may present in asthma. Overexpression of MUC5AC, MUC5B and MUC2 have been described in asthma secretions, but identification of def…

Pulmonary and Respiratory MedicineGoblet cell hyperplasiabusiness.industryMucinMucinsRespiratory Mucosarespiratory systemmedicine.diseaseMucusPhenotypeAsthmarespiratory tract diseasesMuscle hypertrophyMucusfluids and secretionsPhenotypeImmunologyChronic DiseaseMedicineHumansSecretionbusinessAirwayAsthmaCurrent opinion in pulmonary medicine
researchProduct

Against all odds: anti-IgE for intrinsic asthma?

2013

For many years, pathogenetic concepts and the results of clinical trials supported the view that anti-IgE treatment is specifically effective in allergic asthma. However, there is now growing clinical and mechanistic evidence suggesting that treatment with the anti-IgE antibody omalizumab can be effective in patients with intrinsic asthma. Therefore, large and well-controlled clinical trials with anti-IgE are urgently warranted in patients with intrinsic asthma. In addition, there is a need to find new biomarkers which can identify patients with asthma who respond to anti-IgE treatment.

Pulmonary and Respiratory MedicineIntrinsic FactorChest ClinicOmalizumabOmalizumabAsthma PharmacologyImmunoglobulin EAntibodies Monoclonal HumanizedAnti-asthmatic AgentOddsmedicineHumansAnti-Asthmatic Agents1506AsthmaIntrinsic factorbiologybusiness.industrymedicine.diseaseAsthmaImmunity Innaterespiratory tract diseasesAntibodies Anti-IdiotypicClinical trialAsthma MechanismsIntrinsic asthmaImmunologybiology.proteinDisease Progressionbusinessmedicine.drugThorax
researchProduct

Effect of ketotifen on the bronchodilation induced by salbutamol.

1988

Twelve subjects with stable asthma each inhaled two puffs (200 micrograms) of salbutamol on 2 separate days 3 h after double-blind oral administration of ketotifen (two 1-mg capsules) or identical placebo. FEV1 was recorded before and at intervals for 4 h after inhalation of salbutamol. Overall, the FEV1 was significantly greater during the 4-hour period after premedication with ketotifen (p less than 0.02) and the difference between the effect of placebo and ketotifen was statistically significant at 120, 180 and 240 min after salbutamol (p less than 0.05).

Pulmonary and Respiratory MedicineKetotifenAdultMaleBronchiHistamine H1 receptorPlaceboOral administrationForced Expiratory VolumemedicineHumansAlbuterolKetotifenAsthmaInhalationbusiness.industryMiddle Agedmedicine.diseaseAsthmarespiratory tract diseasesBronchodilatationAnesthesiaSalbutamolFemalebusinessmedicine.drugDilatation PathologicRespiration; international review of thoracic diseases
researchProduct

Quantitative analysis of airway obstruction in lymphangioleiomyomatosis

2020

Lymphangioleiomyomatosis (LAM) is a rare, cystic lung disease with progressive pulmonary function loss caused by progressively proliferating LAM cells. The degree of airway obstruction has not been well investigated within the pathogenesis of LAM. Using a combination of ex vivo computed tomography (CT), microCT and histology, the site and nature of airway obstruction in LAM explant lungs was compared with matched control lungs (n=5 each). The total number of airways per generation, total airway counts, terminal bronchioles number and surface density were compared in LAM versus control. Ex vivo CT analysis demonstrated a reduced number of airways from generation 7 on (p<0.0001) in LAM compar…

Pulmonary and Respiratory MedicineLipopolysaccharidesPathologymedicine.medical_specialtyLung NeoplasmsPulmonary function testingPathogenesisOrphan Lung Diseases03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineMedicine and Health SciencesFLOW OBSTRUCTIONMedicineHumans030212 general & internal medicineLymphangioleiomyomatosisBronchiolesLungbusiness.industryHistologyOriginal ArticlesX-Ray MicrotomographyAirway obstructionrespiratory systemmedicine.disease133. Good healthrespiratory tract diseasesAirway Obstruction030228 respiratory systemPULMONARY LYMPHANGIOLEIOMYOMATOSISLymphangioleiomyomatosisHuman medicineAirwaybusinessQuantitative analysis (chemistry)Ex vivoCTThe European Respiratory Journal
researchProduct

Pneumatoceles and pneumothoraces complicating staphylococcal pneumonia: treatment by synchronous independent lung ventilation.

1993

A 54 year old man with a staphylococcal sepsis developed staphylococcal pneumonia complicated by multiple pneumatoceles and bilateral tension pneumothoraces caused by bronchopleural fistulae. Excessive enlargement of the right sided pneumatoceles and a tension pneumothorax not improved by drainage led to mediastinal shift and compression of the right lung. Reversal of the mediastinal shift and closure of the bronchopleural fistulae was achieved by assisted independent lung ventilation.

Pulmonary and Respiratory MedicineLung DiseasesMalemedicine.medical_specialtyHerniaFistulaFistulaMediastinal ShiftPneumonia StaphylococcalmedicineHumansHerniaLungPneumatocelebusiness.industryRespiratory diseasePneumothoraxMiddle AgedPleural Diseasesmedicine.diseaseRespiration ArtificialSurgeryrespiratory tract diseasesPneumoniamedicine.anatomical_structurePneumothoraxBronchial FistulabusinessResearch ArticleThorax
researchProduct

[Methodologic and clinical aspects of the determination of glutathione in induced sputum in bronchopulmonary diseases].

2003

Pulmonary and Respiratory MedicineLung DiseasesPathologymedicine.medical_specialtyTime Factorsbusiness.industryRespiratory Tract DiseasesSputumInduced sputumReproducibility of ResultsBronchial DiseasesGlutathioneGlutathioneSpecimen Handlingchemistry.chemical_compoundchemistryBronchopulmonary diseasesImmunologymedicineHumansbusinessPneumologie (Stuttgart, Germany)
researchProduct